A college degree at 19. A medical school graduate with a Ph.D. at 27.
By the time he completed training in vascular surgery in 2014, Dr. Sapan Desai had cast himself as an ambitious physician, an entrepreneur with an MBA and a prolific researcher published in medical journals.
Then the novel coronavirus hit, and Desai seized the moment. With a Harvard professor, he produced two studies in May that almost instantly disrupted multiple clinical trials amid the pandemic.
One study’s findings were particularly dramatic, reporting that anti-malaria drugs like hydroxychloroquine, which President Donald Trump promoted, were linked to increased deaths of COVID-19 patients. But that study and another were retracted in June by the renowned